Recalculation of the budgetary impact of risperidone use for Autism Spectrum Disorder: a case study using measured demand data, Brazil, 2017-2019.

OBJECTIVE

To analyze the budgetary impact of use of risperidone for autism spectrum disorder (ASD) in the Brazilian National Health System (SUS).

METHODS

This is a case study with a document-based approach, which compared the estimates of the budgetary impact analyses presented in the recommendation reports of the National Commission for the Incorporation of Technologies (CONITEC) for the use of risperidone for ASD with amounts ​​recalculated from measured demand data. The recalculation for children (0-17 years) and adults (≥18 years) was made using data from the Open Health Intelligence Room platform on the dispensing of risperidone in the SUS, considering a three-year time period (2017-2019).

RESULTS

The total budgetary impact over three years of use of risperidone for ASD showed differences between measured demand (children: BRL 10,389,702.70; adults: BRL 15,075,767.80) and that estimated by CONITEC in its recommendation reports (children: R$ 6,579,809.00; adults: R$ 9,877,790.18).

CONCLUSION

The budgetary impact of use of risperidone for ASD, based on measured demand, differed from the impact initially predicted in CONITEC's recommendation reports.